Telix Pharmaceuticals (TLX) director reports 595,000 shares held via Forellan

Rhea-AI Filing Summary

Telix Pharmaceuticals Ltd director Jann Elizabeth Skinner has filed an initial ownership report showing a significant indirect stake in the company. The Form 3 discloses indirect ownership of 595,000 Ordinary Shares held through Forellan Pty Limited, where Ms. Skinner is the sole director and shareholder. This filing records her existing position rather than new share purchases or sales.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Skinner Jann Elizabeth

(Last) (First) (Middle)

C/O TELIX PHARMACEUTICALS LTD

55 FLEMINGTON RD

(Street)

NORTH MELBOURNE 3051

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Telix Pharmaceuticals Ltd [ TLX ]

3a. Foreign Trading Symbol
[TLX]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	595,000	I	Forellan Pty Limited(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Ms. Skinner is the sole director and shareholder of Forellan Pty Limited.

Remarks:

Ex. 24 - Power of Attorney

	/s/ Genevieve Ryan, on behalf of Ms. Jann Skinner	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Telix Pharmaceuticals (TLX) director Jann Elizabeth Skinner report on this Form 3?

She reports an existing indirect ownership of 595,000 Ordinary Shares in Telix Pharmaceuticals. These shares are held through Forellan Pty Limited, providing investors with transparency about her equity stake as a company director.

Are there any buy or sell transactions in this Telix (TLX) Form 3 filing?

No new buy or sell transactions are reported. The Form 3 functions as an initial statement of beneficial ownership, listing Ms. Skinner’s indirect holdings rather than documenting recent trading activity in Telix shares.

How are Jann Elizabeth Skinner’s Telix (TLX) shares held according to the filing?

The 595,000 Telix Ordinary Shares are held indirectly through Forellan Pty Limited. The filing notes that Ms. Skinner is the sole director and shareholder of Forellan, clarifying the control relationship over this shareholding entity.

Why is this Telix Pharmaceuticals (TLX) Form 3 important for investors?

It discloses the scale of a director’s indirect shareholding, 595,000 Ordinary Shares, improving visibility into insider ownership. Such disclosures help investors understand alignment between company leadership and shareholder interests over time.

Does the Telix (TLX) Form 3 indicate any derivative or option positions for Ms. Skinner?

The filing does not list any derivative or option positions. It focuses solely on Ordinary Shares indirectly owned via Forellan Pty Limited, providing a straightforward snapshot of her equity stake at this time.